Literature DB >> 24372619

Stathmin overexpression identifies high risk for lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma patients.

Javed Akhtar1, Zhou Wang, Wen Peng Jiang, Ming Ming Bi, Zhi Ping Zhang.   

Abstract

BACKGROUND AND AIM: Common patterns of the operative failure after Ivor-Lewis esophagectomy in esophageal squamous cell carcinoma (ESCC) patients are locoregional lymph node metastasis. It is clinically significant to investigate the biological markers to predict the subset of patients who are at higher risk of lymphatic metastatic recurrence. Our research aimed to investigate the association between the Stathmin (STMN-1) gene expression and lymphatic metastatic recurrence in pN0 ESCC patients after surgery.
METHODS: One hundred seventy-four patients who suffered from mid-thoracic ESCC and completely resected with Ivor-Lewis esophagectomy were enrolled in our study. The entire patients were restricted to pN0 ESCC. Tissue specimens were examined for STMN-1 expression levels by immunohistochemistry and Western blotting methods. The correlation of STMN-1 levels with clinicopathological variables, prognosis, and metastatic potential was analyzed.
RESULTS: One hundred patients had STMN-1 protein overexpression (57.47%), and the patients with overexpression were accompanied by significantly higher rate of lymphatic metastatic recurrence as compared with patients who had low STMN-1 expression (P = 0.003). Multivariable Cox regression analysis revealed that the STMN-1 protein expression and T classification were independent factors to predict the lymphatic metastatic recurrence (P = 0.007, P = 0.000, respectively).
CONCLUSIONS: Even pN0 ESCC are a potential to lymphatic metastatic recurrence. Stathmin overexpression can be used as a marker to identify those patients who are at high risk for lymphatic metastatic recurrence in pN0 ESCC after an Ivor-Lewis esophagectomy.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  esophageal squamous cell carcinoma; lymphatic metastatic recurrence; stathmin-1

Mesh:

Substances:

Year:  2014        PMID: 24372619     DOI: 10.1111/jgh.12498

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma.

Authors:  Shuai Wang; Javed Akhtar; Zhou Wang
Journal:  Tumour Biol       Date:  2015-05-06

2.  TNFAIP8 overexpression: a potential predictor of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor Lewis esophagectomy.

Authors:  Zhenguo Sun; Xiangyan Liu; Jee Hoon Song; Yulan Cheng; Yu Liu; Yang Jia; Stephen J Meltzer; Zhou Wang
Journal:  Tumour Biol       Date:  2016-02-17

3.  MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells.

Authors:  Michelle J Nyhan; Tracey R O'Donovan; Antonius W M Boersma; Erik A C Wiemer; Sharon L McKenna
Journal:  BMC Cancer       Date:  2016-02-15       Impact factor: 4.430

Review 4.  Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments.

Authors:  Rong Biaoxue; Cai Xiguang; Liu Hua; Yang Shuanying
Journal:  J Transl Med       Date:  2016-09-27       Impact factor: 5.531

5.  Overexpression of stathmin plays a pivotal role in the metastasis of esophageal squamous cell carcinoma.

Authors:  Gaijing Han; Zongyong Wu; Nan Zhao; Lanping Zhou; Fang Liu; Fangfei Niu; Yang Xu; Xiaohang Zhao
Journal:  Oncotarget       Date:  2017-06-27

6.  miR‑193b exhibits mutual interaction with MYC, and suppresses growth and metastasis of osteosarcoma.

Authors:  Jinjian Gao; Sai Ma; Fan Yang; Xu Chen; Wei Wang; Jianping Zhang; Yufang Li; Tao Wang; Lequn Shan
Journal:  Oncol Rep       Date:  2020-04-29       Impact factor: 3.906

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.